Abstract

ObjectivesTo examine whether combined vitamin D and calcium supplementation improves insulin sensitivity, insulin secretion, β-cell function, inflammation and metabolic markers.Design6-month randomized, placebo-controlled trial.ParticipantsNinety-five adults with serum 25-hydroxyvitamin D [25(OH)D] ≤55 nmol/L at risk of type 2 diabetes (with prediabetes or an AUSDRISK score ≥15) were randomized. Analyses included participants who completed the baseline and final visits (treatment n = 35; placebo n = 45).InterventionDaily calcium carbonate (1,200 mg) and cholecalciferol [2,000–6,000 IU to target 25(OH)D >75 nmol/L] or matching placebos for 6 months.MeasurementsInsulin sensitivity (HOMA2%S, Matsuda index), insulin secretion (insulinogenic index, area under the curve (AUC) for C-peptide) and β-cell function (Matsuda index x AUC for C-peptide) derived from a 75 g 2-h OGTT; anthropometry; blood pressure; lipid profile; hs-CRP; TNF-α; IL-6; adiponectin; total and undercarboxylated osteocalcin.ResultsParticipants were middle-aged adults (mean age 54 years; 69% Europid) at risk of type 2 diabetes (48% with prediabetes). Compliance was >80% for calcium and vitamin D. Mean serum 25(OH)D concentration increased from 48 to 95 nmol/L in the treatment group (91% achieved >75 nmol/L), but remained unchanged in controls. There were no significant changes in insulin sensitivity, insulin secretion and β-cell function, or in inflammatory and metabolic markers between or within the groups, before or after adjustment for potential confounders including waist circumference and season of recruitment. In a post hoc analysis restricted to participants with prediabetes, a significant beneficial effect of vitamin D and calcium supplementation on insulin sensitivity (HOMA%S and Matsuda) was observed.ConclusionsDaily vitamin D and calcium supplementation for 6 months may not change OGTT-derived measures of insulin sensitivity, insulin secretion and β-cell function in multi-ethnic adults with low vitamin D status at risk of type 2 diabetes. However, in participants with prediabetes, supplementation with vitamin D and calcium may improve insulin sensitivity.Trial RegistrationAustralian New Zealand Clinical Trials Registry ACTRN12609000043235

Highlights

  • Low serum 25-hydroxyvitamin D [25(OH)D] concentrations and dietary calcium intake have been associated with impaired insulin sensitivity or secretion in people at high risk of type 2 diabetes [1,2]

  • There were no significant changes in insulin sensitivity, insulin secretion and b-cell function, or in inflammatory and metabolic markers between or within the groups, before or after adjustment for potential confounders including waist circumference and season of recruitment

  • In a post hoc analysis restricted to participants with prediabetes, a significant beneficial effect of vitamin D and calcium supplementation on insulin sensitivity (HOMA%S and Matsuda) was observed

Read more

Summary

Introduction

Low serum 25-hydroxyvitamin D [25(OH)D] concentrations and dietary calcium intake have been associated with impaired insulin sensitivity or secretion in people at high risk of type 2 diabetes [1,2]. Some studies have reported a beneficial effect on insulin sensitivity [5,6,7,8,9] and/or secretion [6,10,11] whereas several others failed to demonstrate any effect [12,13,14,15,16,17,18,19,20,21,22,23] Among these studies, only one trial over 16 weeks has investigated the combined effects of calcium and vitamin D supplementation on insulin sensitivity and secretion in people at high risk of type 2 diabetes [10]. It is clear that further welldesigned longer-term clinical trials are needed to evaluate the efficacy of combined calcium and vitamin D supplementation on type 2 diabetes risk

Objectives
Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call